Sparsomycin

Identification

Name
Sparsomycin
Accession Number
DB04222  (EXPT02949)
Type
Small Molecule
Groups
Experimental
Description

An antitumor antibiotic produced by Streptomyces sparsogenes. It inhibits protein synthesis in 70S and 80S ribosomal systems. [PubChem]

Structure
Thumb
Synonyms
Not Available
External IDs
NSC-59729 / U-19183
Categories
UNII
6C940P63E7
CAS number
Not Available
Weight
Average: 361.437
Monoisotopic: 361.076612113
Chemical Formula
C13H19N3O5S2
InChI Key
XKLZIVIOZDNKEQ-CLQLPEFOSA-N
InChI
InChI=1S/C13H19N3O5S2/c1-8-10(12(19)16-13(20)14-8)3-4-11(18)15-9(5-17)6-23(21)7-22-2/h3-4,9,17H,5-7H2,1-2H3,(H,15,18)(H2,14,16,19,20)/b4-3+/t9-,23+/m0/s1
IUPAC Name
(2E)-N-[(2S)-1-hydroxy-3-[(R)-(methylsulfanyl)methanesulfinyl]propan-2-yl]-3-(6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)prop-2-enamide
SMILES
CSC[[email protected]](=O)C[[email protected]](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Sparsomycin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Sparsomycin.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Sparsomycin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sparsomycin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Sparsomycin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Sparsomycin.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Sparsomycin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Sparsomycin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Sparsomycin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Sparsomycin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparsomycin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Sparsomycin.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Sparsomycin.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Sparsomycin.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Sparsomycin.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Sparsomycin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sparsomycin.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Sparsomycin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Sparsomycin.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Sparsomycin.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Henricus C. J. Ottenheijm, "Sparsomycin (SC-RS) compounds having antitumor activity, a process for their preparation and pharmaceutical compositions containing sparsomycin (SC-RS) compounds." U.S. Patent US4820712, issued April, 1986.

US4820712
General References
Not Available
External Links
PubChem Compound
9543443
PubChem Substance
46505251
ChemSpider
7822406
ChEMBL
CHEMBL105720
HET
SPS
PDB Entries
1m90 / 1njm / 1njn / 1vq8 / 1vq9 / 5dgf / 5dgv / 5tgm

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.59 mg/mLALOGPS
logP-1.3ALOGPS
logP-2.5ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)9.93ChemAxon
pKa (Strongest Basic)1.66ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area124.6 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity91.67 m3·mol-1ChemAxon
Polarizability35.53 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8944
Blood Brain Barrier-0.8279
Caco-2 permeable-0.6471
P-glycoprotein substrateSubstrate0.5232
P-glycoprotein inhibitor INon-inhibitor0.8592
P-glycoprotein inhibitor IINon-inhibitor0.9974
Renal organic cation transporterNon-inhibitor0.9232
CYP450 2C9 substrateNon-substrate0.7127
CYP450 2D6 substrateNon-substrate0.8125
CYP450 3A4 substrateSubstrate0.5161
CYP450 1A2 substrateNon-inhibitor0.7752
CYP450 2C9 inhibitorNon-inhibitor0.8087
CYP450 2D6 inhibitorNon-inhibitor0.8899
CYP450 2C19 inhibitorNon-inhibitor0.7924
CYP450 3A4 inhibitorNon-inhibitor0.6771
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9919
Ames testNon AMES toxic0.623
CarcinogenicityNon-carcinogens0.8003
BiodegradationNot ready biodegradable0.7831
Rat acute toxicity2.5203 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8591
hERG inhibition (predictor II)Non-inhibitor0.8647
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Pyrimidones
Alternative Parents
Hydropyrimidines / Vinylogous amides / Heteroaromatic compounds / Ureas / Sulfoxides / Secondary carboxylic acid amides / Lactams / Sulfinyl compounds / Sulfenyl compounds / Azacyclic compounds
show 7 more
Substituents
Pyrimidone / Hydropyrimidine / Vinylogous amide / Heteroaromatic compound / Carboxamide group / Lactam / Secondary carboxylic acid amide / Sulfoxide / Urea / Sulfenyl compound
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 03:39